Crystalline forms of therapeutic compounds and uses thereof

• US 9,790,232 B2
• Filed: 12/28/2015
• Issued: 10/17/2017
• Est. Priority Date: 11/01/2013
• Status: Active Grant

• Current Assignee: Kala Bio, Inc.
• Original Assignee: Kala Pharmaceuticals, Inc.
• Inventors: Enlow, Elizabeth, Nguyen, Minh Ngoc, Ong, Winston Zapanta
• Primary Examiner(s): Ward, Paul V
• Application Number:
  US14/981,105
• Publication Number:
  US 20160115176A1
• Time in Patent Office: 659 Days
• CPC Class Codes: A61K 31/517 ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61K 9/10 Dispersions; Emulsions A61K9/06 takes precedence; composition of dispersions, emulsions A61K47/00
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/146 with organic macromolecular compounds
• CPC Class Codes: A61K 9/5021 Organic macromolecular compounds
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07B 2200/13 Crystalline forms, e.g. polymorphs
• CPC Class Codes: C07D 491/107 with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

Described herein are certain crystalline forms of Compound 3, as well as pharmaceutical compositions employing the crystalline forms. Also provided are particles (e.g., nanoparticles) comprising such crystalline forms or pharmaceutical compositions. In certain examples, the particles are mucus penetrating particles (MPPs). The present invention further relates to methods of treating or preventing diseases using crystalline forms or pharmaceutical compositions.

Claims

1. A crystalline form of 7-(3-(4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-yloxy)propyl)-2-oxa-7-azaspiro[3.5]nonane, wherein the crystalline Form is crystalline Form B having an X-Ray Powder Diffraction (XRPD) pattern with peaks at about 7.70, 13.53, 17.27, 18.44, 19.73, 23.10 and 26.07±

0.3 degrees two theta or 11.47, 6.54, 5.13, 4.81, 4.50, 3.85 and 3.41±

0.3 Å

in d-spacing.

2. The crystalline Form B of claim 1, wherein said XRPD pattern further has peaks at about 9.87, 12.88, 14.40, 15.45, 21.14 and 26.84±

0.3 degrees two theta or 8.96, 6.87, 6.14, 5.73, 4.20 and 3.32±

0.3 Å

in d-spacing.

3. The crystalline Form B of claim 1, wherein said XRPD pattern further has peaks at about 10.69, 16.42, 18.90, 22.56, and 29.12±

0.3 degrees two theta or 8.27, 5.39, 4.69, 3.94 and 3.06±

0.3 Å

in d-spacing.

4. A process for preparing crystalline Form B of claim 1, wherein said process comprises:

a) crystallizing 7-(3-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-yloxy)propyl)-2-oxa-7-azaspiro[3.5]nonane from a solvent mixture comprising water and acetone; and

b) isolating crystalline Form B of the compound from the solvent mixture.

5. The process of claim 4, wherein the solvent mixture consists of 4:

1 acetone;

water mixture.

6. The process of claim 4, wherein the method further comprises heating the solvent mixture to dissolve the 7-(3-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinazolin-7-yloxy)propyl)-2-oxa-7-azaspiro[3.5]nonane.

7. The process of claim 4, wherein the method further comprises cooling the solvent mixture to allow crystal formation.

8. The process of claim 4, wherein said isolated crystalline Form B has an XRPD pattern further having peaks at about 9.87, 12.88, 14.40, 15.45, 21.14 and 26.84±

0.3 degrees two theta or 8.96, 6.87, 6.14, 5.73, 4.20 and 3.32±

0.3 Å

in d-spacing.

9. The process of claim 4, wherein said crystalline Form B has an XRPD pattern with peaks at about 10.69, 16.42, 18.90, 22.56, and 29.12±

0.3 degrees two theta or 8.27, 5.39, 4.69, 3.94 and 3.06±

0.3 Å

in d-spacing.

10. The process of claim 4, wherein said crystalline Form B has an XRPD pattern with peaks at about 7.70, 9.87, 10.69, 12.88, 13.53, 14.40, 15.45, 16.42, 17.27, 18.44, 18.90, 19.73, 21.14, 22.56, 23.10, 26.07, 26.84 and 29.12±

0.3 degrees two theta or 11.47, 8.96, 8.27, 6.87, 6.54, 6.14, 5.73, 5.39, 5.13, 4.81, 4.69, 4.50, 4.20, 3.94, 3.85, 3.41, 3.32 and 3.06±

0.3 Å

in d-spacing.

11. A pharmaceutical composition comprising the crystalline form of claim 1, the composition further comprising a pharmaceutically acceptable carrier.

12. A pharmaceutical composition comprising:

a plurality of coated particles, comprising;

a core particle comprising a crystalline form of claim 1, wherein the crystalline form constitutes at least about 80 wt % of the core particle; and

a coating comprising one or more surface-altering agents surrounding the core particle.

13. The pharmaceutical composition of claim 12, wherein the one or more surface-altering agents comprises a triblock copolymer comprising a hydrophilic block-hydrophobic block-hydrophilic block configuration, wherein the hydrophobic block has a molecular weight of at least about 2 kDa, and the hydrophilic blocks constitute at least about 15 wt % of the triblock copolymer.

14. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is suitable for topical administration.

15. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is suitable for injection.

16. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is suitable for delivery to the eye.

17. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is suitable for oral administration.

18. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition is suitable for inhalation.

19. A method of treating an ocular disease comprising administering to a subject in need thereof a therapeutically effective amount of the crystalline form of claim 1 or the pharmaceutical composition of claim 12.

20. The method of claim 19, wherein the ocular disease is retinopathy, age-related macular degeneration (AM D), corneal neovascularization, diabetic macular edema, or retinal vein occlusion.